Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy.

摘要: An expanding knowledge of the signalling pathways involved in cell cycle has led to great improvements understanding molecular events carcinogenesis. The past decade seen substantial advances with introduction several classes targeted therapeutics for treatment various cancers and autoimmune disorders. However, question arises as whether pregnant women can take advantage these new treatments view potential risks fetus. Published work suggests that biological agents, like traditional treatments, have affect fetus, should, therefore, be used caution during pregnancy. when is clearly indicated magnitude risk fetus might not reach standard chemotherapy. In circumstances where better alternative do exist, or failure use would result suboptimum patient care survival, risk-benefit analysis favour potentially effective